Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia
NCT: NCT07659938 · NOT_YET_RECRUITING
Brief Summary
This preliminary, randomized, double-blind, placebo-controlled clinical trial will evaluate frontal gamma coherence neurofeedback in adults with schizophrenia. Thirty participants will be randomly assigned to receive either active neurofeedback or placebo neurofeedback using a study-provided mobile platform. Participants will complete baseline assessments in person at the University of California San Diego, receive training on home use of the neurofeedback platform, and complete twice-weekly 30-minute sessions at home for 12 weeks. Participants will return for midpoint and end-of-treatment assessments to evaluate feasibility, tolerability, cognitive outcomes, and neurophysiological target engagement.
Frequently Asked Questions
What is Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia?
Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia is a clinical trial registered under NCT07659938. Current status: NOT_YET_RECRUITING.
What is the status of NCT07659938?
The current status of NCT07659938 (Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia) is: NOT_YET_RECRUITING.
When did Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia start?
Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia started on 2027-04.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.